Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06FKC
|
||||
| Former ID |
DIB006653
|
||||
| Drug Name |
Eltoprazine
|
||||
| Synonyms |
Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Aggressive non-hodgkin's lymphoma [ICD9: 200, 201, 202, 202.8, 208.9; ICD10:C81, C81-C86, C82-C85, C91-C95] | Phase 2 | [1] | ||
| Company |
Amarantus bioscience; psychogenics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H16N2O2
|
||||
| Canonical SMILES |
C1CN(CCN1)c2cccc3OCCOc23
|
||||
| InChI |
1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2
|
||||
| InChIKey |
WVLHGCRWEHCIOT-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 98224-03-4
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [2] | |
| 5-hydroxytryptamine 2C receptor | Target Info | Antagonist | [2] | ||
| 5-hydroxytryptamine 1B receptor | Target Info | Agonist | [2], [3] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04020:Calcium signaling pathway | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01266174) Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. | ||||
| REF 3 | Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.